Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) will likely be posting its resultson Monday, May 11th. Analysts expect Shionogi & Co., Ltd. Unsponsored ADR to post earnings of $0.15 per share and revenue of $895.5180 million for the quarter.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last released its earnings results on Friday, January 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.09. The firm had revenue of $966.53 million for the quarter, compared to analyst estimates of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%. On average, analysts expect Shionogi & Co., Ltd. Unsponsored ADR to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shionogi & Co., Ltd. Unsponsored ADR Stock Performance
SGIOY remained flat at $9.86 during midday trading on Monday. The company’s stock had a trading volume of 10,340 shares, compared to its average volume of 98,851. The stock has a market capitalization of $16.78 billion, a PE ratio of 12.97, a P/E/G ratio of 0.73 and a beta of 0.10. The firm has a fifty day simple moving average of $10.74 and a two-hundred day simple moving average of $9.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.21 and a current ratio of 5.84. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.38 and a 12-month high of $12.00.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Articles
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
